Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.
ALK rearrangement
BRAF A598-T599insV mutation
lung adenocarcinoma
non-small cell lung cancer
resistance to alectinib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
07
2022
accepted:
10
10
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved the prognosis of advanced-stage non-small cell lung cancer (NSCLC) with ALK rearrangement, but resistance mechanisms limit their efficacy. We describe the case of a 63-year-old man with a stage cIVA
Identifiants
pubmed: 36419902
doi: 10.3389/fonc.2022.985446
pmc: PMC9677532
doi:
Types de publication
Case Reports
Langues
eng
Pagination
985446Informations de copyright
Copyright © 2022 Pasau, Wauters, Wauters, Duplaquet, Pirard, Pop-Stanciu, D’Haene, Dupont, Vander Borght, Rondelet and Ocak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lung Cancer. 2014 Oct;86(1):22-8
pubmed: 25172266
Clin Cancer Res. 2019 Nov 15;25(22):6671-6682
pubmed: 31439588
Melanoma Res. 2017 Oct;27(5):507-510
pubmed: 28800030
Nat Rev Clin Oncol. 2012 Apr 03;9(5):268-77
pubmed: 22473102
Transl Lung Cancer Res. 2020 Dec;9(6):2545-2556
pubmed: 33489817
Clin Cancer Res. 2019 Jan 1;25(1):158-165
pubmed: 30224342
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
J Clin Endocrinol Metab. 2016 Nov;101(11):4413-4420
pubmed: 27571181
Pharmaceutics. 2021 Sep 15;13(9):
pubmed: 34575554
Lung Cancer. 2020 Aug;146:78-85
pubmed: 32521388
Cancers (Basel). 2015 Apr 30;7(2):763-83
pubmed: 25941796
Front Oncol. 2022 Apr 06;12:863461
pubmed: 35463328
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Mol Sci. 2020 Apr 19;21(8):
pubmed: 32325863
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Eur Respir J. 2015 May;45(5):1403-14
pubmed: 25657019
Medicine (Baltimore). 2021 Feb 26;100(8):e24917
pubmed: 33663128
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Case Rep Oncol. 2019 Nov 21;12(3):872-879
pubmed: 31824282
Front Oncol. 2022 Jul 13;12:882940
pubmed: 35912223
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378